Porcine-derived enoxaparin and consent: implications for prescribers

Venous thromboembolism is a major cause of preventable morbidity and mortality among hospitalised patients, and low-molecular-weight heparins such as enoxaparin are widely prescribed for thromboprophylaxis in surgical practice. Enoxaparin is derived from porcine intestinal mucosa, a characteristic that may be significant for some Muslim patients whose religious beliefs prohibit the use of porcine products. As healthcare increasingly emphasises informed consent, shared decision-making and personalised care, questions arise about whether the biological origin of enoxaparin may constitute material information within prescribing consultations. This article explores the ethical, legal and practical implications of prescribing porcine-derived enoxaparin to Muslim patients. Drawing on contemporary literature, Islamic perspectives on medical necessity and the principles established in Montgomery v Lanarkshire Health Board, it examines whether the porcine origin of enoxaparin may constitute material information for some patients. The article argues that material information in prescribing may extend beyond clinical risks and benefits to include information that is morally, culturally or religiously significant to individual patients and may influence treatment acceptability.